- Home
- PDT vs UPB Comparison
PDT vs UPB Comparison
Compare PDT & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDT
- UPB
- Stock Information
- Founded
- PDT 1989
- UPB 2021
- Country
- PDT United States
- UPB United States
- Employees
- PDT N/A
- UPB N/A
- Industry
- PDT Finance Companies
- UPB
- Sector
- PDT Finance
- UPB
- Exchange
- PDT Nasdaq
- UPB NYSE
- Market Cap
- PDT 644.8M
- UPB 521.3M
- IPO Year
- PDT N/A
- UPB 2024
- Fundamental
- Price
- PDT $13.32
- UPB $11.13
- Analyst Decision
- PDT
- UPB Strong Buy
- Analyst Count
- PDT 0
- UPB 4
- Target Price
- PDT N/A
- UPB $56.50
- AVG Volume (30 Days)
- PDT 145.6K
- UPB 500.3K
- Earning Date
- PDT 01-01-0001
- UPB 08-14-2025
- Dividend Yield
- PDT 8.88%
- UPB N/A
- EPS Growth
- PDT N/A
- UPB N/A
- EPS
- PDT N/A
- UPB N/A
- Revenue
- PDT N/A
- UPB $2,296,000.00
- Revenue This Year
- PDT N/A
- UPB N/A
- Revenue Next Year
- PDT N/A
- UPB N/A
- P/E Ratio
- PDT N/A
- UPB N/A
- Revenue Growth
- PDT N/A
- UPB N/A
- 52 Week Low
- PDT $8.77
- UPB $5.14
- 52 Week High
- PDT $13.05
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- PDT 66.70
- UPB N/A
- Support Level
- PDT $13.01
- UPB N/A
- Resistance Level
- PDT $13.18
- UPB N/A
- Average True Range (ATR)
- PDT 0.14
- UPB 0.00
- MACD
- PDT 0.01
- UPB 0.00
- Stochastic Oscillator
- PDT 94.32
- UPB 0.00
About PDT John Hancock Premium Dividend Fund
John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest growth of capital. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.